» Authors » Tatyana Dekhtyar

Tatyana Dekhtyar

Explore the profile of Tatyana Dekhtyar including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 29
Citations 395
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Randolph J, Li T, Krueger A, Heyman H, Chen H, Bow D, et al.
Bioorg Med Chem Lett . 2020 Feb; 30(7):126986. PMID: 32046903
Our HCV research program investigated novel 2'-dihalogenated nucleoside HCV polymerase inhibitors and identified compound 1, a 5'-phosphoramidate prodrug of 2'-deoxy-2'-α-bromo-β-chloro uridine. Although 1 had a favorable in vitro activity profile...
2.
Krueger A, Chen H, Randolph J, Brown B, Halvorsen G, Heyman H, et al.
Bioorg Med Chem . 2019 Nov; 28(1):115208. PMID: 31740203
Hepatitis C virus (HCV) nucleoside inhibitors have been a key focus of nearly 2 decades of HCV drug research due to a high barrier to drug resistance and pan-genotypic activity...
3.
Schnell G, Krishnan P, Tripathi R, Beyer J, Reisch T, Irvin M, et al.
PLoS One . 2018 Oct; 13(10):e0205186. PMID: 30286205
Hepatitis C virus (HCV) is genetically diverse and includes 7 genotypes and 67 confirmed subtypes, and the global distribution of each HCV genotype (GT) varies by geographic region. In this...
4.
Ng T, Pilot-Matias T, Tripathi R, Schnell G, Krishnan P, Reisch T, et al.
Viruses . 2018 Aug; 10(9). PMID: 30154359
Glecaprevir (an NS3/4A protease inhibitor) and pibrentasvir (an NS5A inhibitor) are potent and pangenotypic hepatitis C virus (HCV) direct-acting antivirals. This report describes the baseline polymorphisms and treatment-emergent substitutions in...
5.
Krishnan P, Pilot-Matias T, Schnell G, Tripathi R, Ng T, Reisch T, et al.
Antimicrob Agents Chemother . 2018 Aug; 62(10). PMID: 30061289
Over 2,200 patients infected with hepatitis C virus (HCV) genotypes (GT) 1 to 6, with or without cirrhosis, who were treatment naive or experienced to interferon, ribavirin, and/or sofosbuvir were...
6.
Wagner R, Randolph J, Patel S, Nelson L, Matulenko M, Keddy R, et al.
J Med Chem . 2018 Apr; 61(9):4052-4066. PMID: 29653491
Curative interferon and ribavirin sparing treatments for hepatitis C virus (HCV)-infected patients require a combination of mechanistically orthogonal direct acting antivirals. A shared component of these treatments is usually an...
7.
Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Dekhtyar T, et al.
Antimicrob Agents Chemother . 2017 Nov; 62(2). PMID: 29180522
Glecaprevir and pibrentasvir are hepatitis C virus (HCV) pangenotypic inhibitors targeting NS3/4A protease and NS5A, respectively. This once-daily, fixed-dose combination regimen demonstrated high sustained virologic response 12 weeks postdosing (SVR)...
8.
Ng T, Tripathi R, Reisch T, Lu L, Middleton T, Hopkins T, et al.
Antimicrob Agents Chemother . 2017 Nov; 62(1). PMID: 29084747
Glecaprevir (formerly ABT-493) is a novel hepatitis C virus (HCV) NS3/4A protease inhibitor (PI) with pangenotypic activity. It inhibited the enzymatic activity of purified NS3/4A proteases from HCV genotypes 1...
9.
Schnell G, Tripathi R, Krishnan P, Beyer J, Reisch T, Irvin M, et al.
J Med Virol . 2017 Aug; 90(1):109-119. PMID: 28842997
Treatment of HCV genotype (GT) 2-infected Japanese patients with paritaprevir (NS3/4A inhibitor boosted with ritonavir) and ombitasvir (NS5A inhibitor) without ribavirin for 12 weeks in the phase 2 study M12-536,...
10.
Ng T, Krishnan P, Pilot-Matias T, Kati W, Schnell G, Beyer J, et al.
Antimicrob Agents Chemother . 2017 Feb; 61(5). PMID: 28193664
Pibrentasvir (ABT-530) is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with 50% effective concentration (EC) values ranging from 1.4 to 5.0 pM against HCV replicons containing NS5A...